REPORT FROM THE 2009 AAN ANNUAL MEETING – Two studies have investigated the potential benefits of rituximab, a monoclonal antibody that targets CD20 B cells, in primary- and secondary-progressive MS (PPMS, SPMS).
It takes 30 seconds or login using your email address
Please enter the email address that you registered the newsletter with
